{
  "run_id": "RUN_20260204_132700_1fed028ce5fb",
  "timestamp": "2026-02-04T14:36:06.612110",
  "document": "01_Article_Iptacopan C3G Trial.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/PAPERS/01_Article_Iptacopan C3G Trial.pdf",
  "pipeline_version": "0.8",
  "total_recommendation_sets": 1,
  "total_recommendations": 2,
  "recommendation_sets": [
    {
      "guideline_name": "Current guideline recommendations for C3 glomerulopathy",
      "guideline_year": null,
      "organization": "Current clinical guidelines",
      "target_condition": "C3 glomerulopathy",
      "target_population": null,
      "recommendations": [
        {
          "recommendation_id": "rec_01_Article_Iptacopan C3G Trial_1",
          "recommendation_type": "treatment",
          "population": "patients with C3 glomerulopathy",
          "condition": "C3 glomerulopathy",
          "severity": "not specified",
          "action": "supportive care with blockade of the renin-angiotensin-aldosterone system",
          "action_description": null,
          "preferred": "angiotensin-converting enzyme inhibitors or AT1 receptor blockers",
          "alternatives": [],
          "dosing": [],
          "taper_target": null,
          "duration": null,
          "stop_window": null,
          "evidence_level": "expert_opinion",
          "strength": "conditional",
          "references": [],
          "source": "01_Article_Iptacopan C3G Trial",
          "source_text": "Current guideline recommendations rely on supportive care (ie, blockade of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme inhibitors or AT1 receptor blockers)",
          "page_num": null
        },
        {
          "recommendation_id": "rec_01_Article_Iptacopan C3G Trial_2",
          "recommendation_type": "treatment",
          "population": "patients with C3 glomerulopathy",
          "condition": "C3 glomerulopathy",
          "severity": "not specified",
          "action": "consider immunosuppression",
          "action_description": null,
          "preferred": null,
          "alternatives": [
            "mycophenolic mofetil",
            "corticosteroids"
          ],
          "dosing": [],
          "taper_target": null,
          "duration": null,
          "stop_window": null,
          "evidence_level": "expert_opinion",
          "strength": "conditional",
          "references": [],
          "source": "01_Article_Iptacopan C3G Trial",
          "source_text": "with or without immunosuppression (eg, mycophenolic mofetil or corticosteroids)",
          "page_num": null
        }
      ],
      "source_document": "01_Article_Iptacopan C3G Trial",
      "extraction_confidence": 0.85
    }
  ]
}